Fust Matthew K 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Sep 30, 2025
Insider Transaction Report
Form 4
Fust Matthew K
Director
Transactions
- Sale
Common Stock
2025-09-26$44.75/sh−16,000$716,000→ 22,836 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-26−10,000→ 2,092 totalExercise: $1.91Exp: 2028-03-16→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2025-09-26$1.91/sh+10,000$19,100→ 38,836 total
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2024.
- [F2]The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $44.75 per share.
- [F3]1/3rd of the options vested on February 16, 2019, and 1/36th of the options vested monthly thereafter.